LZ-167 -- LK-183
Our drug LZ-167, has passed efficacy tests in in vitro preclinicals, in in vivo animal experimental models and in off-label clinical trials in humans.
By comparing different drugs, we found that our drug compared to the current treatments available for cancer has an important effect against tumor cell proliferation, neoangiogenesis, metastasis production and tumor microenvironment balance. It also has no undesirable effects and has beneficial effects because it is anxiolytic, antidepressant, analgesic, and anti-inflammatory.
In our LK-183 trials, it has been shown to prevent the migration of tumor cells, which makes their ability to invade and therefore the production of distant metastases impossible.
Therefore, LK-183 can be effective as a Preventive Treatment against cancer and as a treatment to avoid metastasis.